DMN:FRA
Diamyd Medical AB
0,063 €
arrow_downward
-0,63%(-0,00040) 1D
13 նոյ, 22:00:00 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
139,51 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
139,51 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
Foreign Policy Journal
·
22 րոպե առաջ
BigBear.ai (NASDAQ: BBAI) Swings To A $91.9 Million Quarterly Loss Even As Federal AI Contracts Surpass $225 Million
Yahoo Finance
·
8 ժամ առաջ
SpaceX’s S&P 500 Bid Gets New Life as Musk Pitches Tesla Merger
AP News
·
23 ժամ առաջ
Microsoft outage shows the risks of relying on a single technology provider for essential services
Investor's Business Daily
·
2 ժամ առաջ
New Rally Shaky, But Many Stocks Set Up. Nvidia, Anthropic Ahead.
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB